Nano/microparticle Formulations for Universal Influenza Vaccines

Hendy, Dylan A.; Amouzougan, Eva A.; Young, Isabella C.; Bachelder, Eric M.; Ainslie, Kristy M.

doi:10.1208/s12248-021-00676-9

Cited by 6 publications

(5 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nano‐vaccine technology involves encapsulation of antigens into nanoparticles or the displaying antigens on their surface. This approach protects antigens from premature proteolytic degradation, improves stability, possesses good adjuvant properties, facilitates targeted delivery and controls their release, leading to enhanced antigen presentation, and subsequently results in increased vaccine antigenicity and immunogenicity [ 50 , 51 ]. A study demonstrated that two‐component nanoparticles that co‐display diverse influenza HA trimers induced broadly protective antibody responses to heterologous viruses in mice, ferrets and nonhuman primates (NHPs) [ 52 ].…”

Section: Universal Vaccine Platformsmentioning

confidence: 99%

Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines

Lim,

Komarasamy,

Adnan

et al. 2024

Influenza Resp Viruses

View full text Add to dashboard Cite

Every year, influenza virus infections cause significant morbidity and mortality worldwide. They pose a substantial burden of disease, in terms of not only health but also the economy. Owing to the ability of influenza viruses to continuously evolve, annual seasonal influenza vaccines are necessary as a prophylaxis. However, current influenza vaccines against seasonal strains have limited effectiveness and require yearly reformulation due to the virus undergoing antigenic drift or shift. Vaccine mismatches are common, conferring suboptimal protection against seasonal outbreaks, and the threat of the next pandemic continues to loom. Therefore, there is a great need to develop a universal influenza vaccine (UIV) capable of providing broad and durable protection against all influenza virus strains. In the quest to develop a UIV that would obviate the need for annual vaccination and formulation, a multitude of strategies is currently underway. Promising approaches include targeting the highly conserved epitopes of haemagglutinin (HA), neuraminidase (NA), M2 extracellular domain (M2e) and internal proteins of the influenza virus. The identification and characterization of broadly neutralizing antibodies (bnAbs) targeting conserved regions of the viral HA protein, in particular, have provided important insight into novel vaccine designs and platforms. This review discusses universal vaccine approaches presently under development, with an emphasis on those targeting the highly conserved stalk of the HA protein, recent technological advancements used and the future prospects of a UIV in terms of its advantages, developmental obstacles and potential shortcomings.

show abstract

Section: Universal Vaccine Platformsmentioning

confidence: 99%

Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines

Lim,

Komarasamy,

Adnan

et al. 2024

Influenza Resp Viruses

View full text Add to dashboard Cite

show abstract

“…Surface modifications with hydrophilic polymers such as PEG are essential for reducing nonspecific interactions with serum proteins, decreasing susceptibility to opsonization, and deferring uptake by phagocytosis, thereby expanding the drug half-life and further affecting the biodistribution and pharmacokinetic profile of the drug, and are thus considered the 'gold-standard' of cloaking agent systems. Polymeric nanoparticles can be divided into two types: nanocapsules and nanospheres [54].…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

“…These are made up of an inner hydrophobic core (which can include medications that are poorly water soluble) and an exterior hydrophilic polymer (such as PEG, which can extend circulation time and improve accumulation). Polymeric micelles, for example, have received a lot of interest as drug delivery agents with substantial therapeutic promise [54]. One of the most appealing nanotechnologies for improving the water solubility and stability of otherwise technologically constrained (poorly water soluble and unstable) pharmaceuticals is drug encapsulation with polymeric micelles.…”

Section: Micellesmentioning

confidence: 99%

“…The synthesis of metallic nanoparticles can be divided into two approaches: the 'bottom-up' (or self-assembly) approach refers to building the nanoparticle level by level (e. g., atom by atom or cluster by cluster), and the 'topdown' approach uses chemical or physical methods to reduce the inorganic material to its nanosized form. The reaction parameters (pH, temperature, duration, or concentration) can be employed to adjust nanoparticle attributes (size and shape), whilst the reducing agent used can influence aspects such as loading capacity, release, and aggregation profiles [54,60].…”

Section: Inorganic Nanoparticlesmentioning

confidence: 99%

See 1 more Smart Citation

A Comprehensive Study of Recent Breakthroughs in the Management of Dynamic Viral Infections

SHARMA,

SINGH

2023

Int J Curr Pharm Sci

View full text Add to dashboard Cite

Infectious diseases have been known to human civilization since the dawn of humanity. Infectious disorders are caused by various microorganisms (bacteria, fungi, and viruses). Viruses are the most well-known of all microbes. Viruses are the most well-known type of microbe. They are ultramicroscopic intracellular parasites that require a host cell to survive and reproduce. Viruses have either DNA or RNA as genetic material and have been linked to various diseases in humans, animals, and plants. The war between viruses and humans is ongoing, as both will employ diverse ways to oppose each other. Antiviral treatment and improved technology development a time-consuming process. Despite advanced instruments and tight quality control systems, only a few numbers of antiviral medications or treatment technologies are approved for human use. The cause could be side effects or antiviral medication resistance. Increased understanding of viruses, their infection mechanisms, and the rapid evolution of novel antiviral methods and methodologies will accelerate the creation of novel antiviral medications. This review focuses on the worldwide picture of drug discovery for infectious diseases and contemporary improved methodologies and antiviral therapy options.

show abstract

“…Influenza A virus will remain a significant threat to global public health for the foreseeable future due to its ability to constantly evolve and generate new variants [1]. The segmented RNA genome and a broad host range critically contribute to the IAV evolution, which has prevented the development of a universal vaccine so far and reduces the efficacy of available vaccines and increases the potential of the emergence of antiviral drug resistance [2,3]. Now, there is emerging evidence that IAV could have a mutualistic relationship with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and cause simultaneous flu and coronavirus disease 2019 (COVID-19) and epidemics in humans [4][5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Anti‐microbial host factor HDAC6 is antagonised by the influenza A virus through host caspases and viral PA

et al. 2023

View full text Add to dashboard Cite

Histone deacetylase 6 (HDAC6), through the repertoire of its substrate proteins, plays a critical role in human physiology, and an aberrant function of HDAC6 contributes to various pathophysiological conditions. HDAC6 is also known to be an anti‐microbial host factor and has been implicated in restricting or clearing the infection of various human viral and bacterial pathogens. However, the state and the mechanisms of its antagonism in infected cells are not understood. Here, we demonstrate that influenza A virus (IAV) antagonises HDAC6 by recruiting both viral and host components. We found that HDAC6 mRNA expression, and consequently, the HDAC6 polypeptide expression is downregulated in human lung epithelial cells during early stage of IAV infection but can be rescued by depleting the expression of viral polymerase acidic (PA) protein, a subunit of IAV RNA polymerase. In addition, during later stage of the infection, the HDAC6 polypeptide undergoes caspase‐mediated cleavage at two sites, generating two cleaved fragments. Both these fragments disappeared when the expression of caspase 3 was depleted in infected cells, whereas only second fragment disappeared when the expression of caspase 6 was depleted. But both fragments disappeared and the level of full‐length HDAC6 polypeptide was rescued when the expression of PA was depleted in infected cells. Collectively, these data indicated that IAV antagonises the HDAC6 by decreasing its expression level in infected cells, both at mRNA and polypeptide level via PA gene, which has been implicated in auxiliary functions like degradation of host mRNA and induction of apoptosis.

show abstract

Nano/microparticle Formulations for Universal Influenza Vaccines

Cited by 6 publications

References 79 publications

Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines

Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines

A Comprehensive Study of Recent Breakthroughs in the Management of Dynamic Viral Infections

Anti‐microbial host factor HDAC6 is antagonised by the influenza A virus through host caspases and viral PA

Contact Info

Product

Resources

About